The Institute for Clinical and Economic Review (ICER) on Friday announced plans to launch the first phase a new program which aims to bolster transparency in the institute’s drug assessment review process.
According to a press release, ICER “will work with its academic collaborators to share executable versions of draft cost-effectiveness models with relevant drug manufacturers during ICER evidence reviews.”
“ICER is committed to ensuring the highest level of transparency in all our work, and this pilot program takes our policies one step further,” noted Dan Ollendorf, PhD, ICER’s Chief Scientific Officer. “We have always made every effort to share information about economic model structure and inputs with manufacturers during our review so that they could understand and critique the models during their development.”
Manufacturers of the interventions and comparators of interest for a review will be required to pay a fee to ICER’s “academic collaborators” to cover costs associated with the production of “sharable executable files and all supporting documentation,” according to the release.
The models will be shared through confidentiality or licensing agreements to protect the researchers’ intellectual property.